A randomized, controlled dose response study of intravenous sodium diethyldithiocarbamate in patients with advanced human immunodeficiency virus infection

Charles S. Kaplan, Eskild A. Petersen, David Yocum, Evan M Hersh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Sodium diethyldithiocarbamate (Imuthiol, DTC) has previously been observed to promote T-cell maturation in animal models and to reduce lymphadenopathy and improve survival in a murine AIDS model. In addition, several clinical studies have suggested that one dosage regimen may be active in patients with HIV infection. We conducted a randomized, controlled dose response study of intravenous DTC in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). Drug associated toxicities included gastrointestinal upset, burning at the infusion site, metallic taste, sneezing, confusional states, hyperactivity, delusional thinking, and myoclonus. Toxicity was ameliorated by dose reduction. The maximally tolerated dose varied for individual patients from 200 mg/m2 weekly to 800 mg/m2 twice weekly. No myelosuppression was observed. In patients with greater than 200 CD4+ cells/uL, a statistically significant reduction of lymphadenopathy occurred; whereas no beneficial effects were observed in patients with less than 200 CD4+ cells/uL. Improvement in symptom score and stabilization of CD4+ count also occured in the treated group, although these trends did not reach statistical significance. Further controlled clinical trials of DTC in earlier HIV infection are warranted.

Original languageEnglish (US)
JournalLife Sciences
Volume45
Issue number22
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Ditiocarb
Virus Diseases
Viruses
Toxicity
HIV
T-cells
Animals
Stabilization
HIV Infections
Acquired Immunodeficiency Syndrome
Murine Acquired Immunodeficiency Syndrome
Taste Disorders
Sneezing
Confusion
Myoclonus
Pharmaceutical Preparations
Maximum Tolerated Dose
Controlled Clinical Trials
CD4 Lymphocyte Count
Drug-Related Side Effects and Adverse Reactions

ASJC Scopus subject areas

  • Pharmacology

Cite this

A randomized, controlled dose response study of intravenous sodium diethyldithiocarbamate in patients with advanced human immunodeficiency virus infection. / Kaplan, Charles S.; Petersen, Eskild A.; Yocum, David; Hersh, Evan M.

In: Life Sciences, Vol. 45, No. 22, 1989.

Research output: Contribution to journalArticle

@article{e7408209d62e415199c556c640e75314,
title = "A randomized, controlled dose response study of intravenous sodium diethyldithiocarbamate in patients with advanced human immunodeficiency virus infection",
abstract = "Sodium diethyldithiocarbamate (Imuthiol, DTC) has previously been observed to promote T-cell maturation in animal models and to reduce lymphadenopathy and improve survival in a murine AIDS model. In addition, several clinical studies have suggested that one dosage regimen may be active in patients with HIV infection. We conducted a randomized, controlled dose response study of intravenous DTC in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). Drug associated toxicities included gastrointestinal upset, burning at the infusion site, metallic taste, sneezing, confusional states, hyperactivity, delusional thinking, and myoclonus. Toxicity was ameliorated by dose reduction. The maximally tolerated dose varied for individual patients from 200 mg/m2 weekly to 800 mg/m2 twice weekly. No myelosuppression was observed. In patients with greater than 200 CD4+ cells/uL, a statistically significant reduction of lymphadenopathy occurred; whereas no beneficial effects were observed in patients with less than 200 CD4+ cells/uL. Improvement in symptom score and stabilization of CD4+ count also occured in the treated group, although these trends did not reach statistical significance. Further controlled clinical trials of DTC in earlier HIV infection are warranted.",
author = "Kaplan, {Charles S.} and Petersen, {Eskild A.} and David Yocum and Hersh, {Evan M}",
year = "1989",
doi = "10.1016/0024-3205(89)90070-2",
language = "English (US)",
volume = "45",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "22",

}

TY - JOUR

T1 - A randomized, controlled dose response study of intravenous sodium diethyldithiocarbamate in patients with advanced human immunodeficiency virus infection

AU - Kaplan, Charles S.

AU - Petersen, Eskild A.

AU - Yocum, David

AU - Hersh, Evan M

PY - 1989

Y1 - 1989

N2 - Sodium diethyldithiocarbamate (Imuthiol, DTC) has previously been observed to promote T-cell maturation in animal models and to reduce lymphadenopathy and improve survival in a murine AIDS model. In addition, several clinical studies have suggested that one dosage regimen may be active in patients with HIV infection. We conducted a randomized, controlled dose response study of intravenous DTC in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). Drug associated toxicities included gastrointestinal upset, burning at the infusion site, metallic taste, sneezing, confusional states, hyperactivity, delusional thinking, and myoclonus. Toxicity was ameliorated by dose reduction. The maximally tolerated dose varied for individual patients from 200 mg/m2 weekly to 800 mg/m2 twice weekly. No myelosuppression was observed. In patients with greater than 200 CD4+ cells/uL, a statistically significant reduction of lymphadenopathy occurred; whereas no beneficial effects were observed in patients with less than 200 CD4+ cells/uL. Improvement in symptom score and stabilization of CD4+ count also occured in the treated group, although these trends did not reach statistical significance. Further controlled clinical trials of DTC in earlier HIV infection are warranted.

AB - Sodium diethyldithiocarbamate (Imuthiol, DTC) has previously been observed to promote T-cell maturation in animal models and to reduce lymphadenopathy and improve survival in a murine AIDS model. In addition, several clinical studies have suggested that one dosage regimen may be active in patients with HIV infection. We conducted a randomized, controlled dose response study of intravenous DTC in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). Drug associated toxicities included gastrointestinal upset, burning at the infusion site, metallic taste, sneezing, confusional states, hyperactivity, delusional thinking, and myoclonus. Toxicity was ameliorated by dose reduction. The maximally tolerated dose varied for individual patients from 200 mg/m2 weekly to 800 mg/m2 twice weekly. No myelosuppression was observed. In patients with greater than 200 CD4+ cells/uL, a statistically significant reduction of lymphadenopathy occurred; whereas no beneficial effects were observed in patients with less than 200 CD4+ cells/uL. Improvement in symptom score and stabilization of CD4+ count also occured in the treated group, although these trends did not reach statistical significance. Further controlled clinical trials of DTC in earlier HIV infection are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0024440536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024440536&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(89)90070-2

DO - 10.1016/0024-3205(89)90070-2

M3 - Article

C2 - 2557513

AN - SCOPUS:0024440536

VL - 45

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 22

ER -